title: Leucapheresis for management of retinopathy in chronic myeloid leukaemia.
abstract: Chronic myeloid leukaemia is a myeloproliferative neoplasm characterised by granulocytic hyperplasia in the bone marrow and the presence of a specific cytogenetic abnormality known as Philadelphia chromosome with fusion of breakpoint cluster region (BCR) and ableson (ABL) genes. Retinopathy is a rare sight-threatening complication of chronic myeloid leukaemia, which occurs due to leucostasis in retinal blood vessels. We report a case of a patient who presented with visual impairment due to leucostasis, who was successfully managed by leucapheresis along with BCR-ABL tyrosine kinase inhibitor.
authors.affiliation: Department of Haematology, Launceston General Hospital, Launceston, Tasmania, Australia.
authors.forename: Muhajir
authors.initials: M
authors.lastname: Mohamed
authors.affiliation: Department of Ophthalmology, Launceston Eye Institute, Launceston, Tasmania, Australia.
authors.forename: Carmen
authors.initials: C
authors.lastname: Oakley
authors.affiliation: Department of Haematology, Launceston General Hospital, Launceston, Tasmania, Australia.
authors.forename: Fiona
authors.initials: F
authors.lastname: McEwen
authors.affiliation: Department of Haematology, Launceston General Hospital, Launceston, Tasmania, Australia.
authors.forename: Georgina
authors.initials: G
authors.lastname: Connelley
mesh_terms: D000069439:Dasatinib / Q000627:therapeutic use; D006801:Humans; D007937:Leukapheresis; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000150:complications*; D008297:Male; D008875:Middle Aged; D010677:Philadelphia Chromosome; D047428:Protein Kinase Inhibitors / Q000627:therapeutic use; D014786:Vision Disorders / Q000209:etiology* / Q000628:therapy*
chemical_list: D047428:Protein Kinase Inhibitors; D000069439:Dasatinib